|
コバヤシ ヒロヒト
Kobayashi Hirohito
小林 博人 所属 医学部 医学科（附属足立医療センター） 職種 准教授 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions. |
| 掲載誌名 | 正式名：International journal of urology : official journal of the Japanese Urological Association 略 称：Int J Urol ISSNコード：09198172/14422042 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 28(1),pp.99-106 |
| 著者・共著者 | ISHIHARA Hiroki†, FUKUDA Hironori, TAKAGI Toshio, KONDO Tsunenori*, TACHIBANA Hidekazu, YOSHIDA Kazuhiko, IIZUKA Junpei, KOBAYASHI Hirohito, ISHIDA Hideki, TANABE Kazunari |
| 発行年月 | 2021/01 |
| 概要 | OBJECTIVES:To compare the efficacy of nivolumab with that of molecular-targeted therapy as a second-line therapy for metastatic renal cell carcinoma using real-world data.METHODS:We retrospectively evaluated patients who received nivolumab or molecular-targeted therapy after the failure of first-line molecular-targeted therapy between January 2008 and December 2019 at two Japanese institutions. Progression-free survival and overall survival after the initiation of second-line therapy were calculated using the Kaplan-Meier method and compared using the log-rank test. Objective response rate was assessed based on the Response Evaluation Criteria in Solid Tumors version 1.1.RESULTS:Among 159 patients, 43 (27%) and 116 (73%) patients received nivolumab and molecular-targeted therapy as second-line therapy, respectively. During follow up (median 11.1 months), 129 (81%) and 98 (62%) patients had disease progression and died, respectively. Progression-free survival was comparable between the two treatments (median 5.06 vs 5.95 months, P = 0.881), whereas overall survival was significantly longer with nivolumab than with molecular-targeted therapy (not reached vs 13.0 months, P = 0.0008). Multivariate analysis further showed that nivolumab therapy was an independent favorable factor for overall survival (hazard ratio 0.33, P = 0.0007). In 151 patients with eligible radiographic data, the objective response rate was significantly higher in nivolumab than in molecular-targeted therapy (n = 14/41 [34%] vs n = 20/110 [18%], P = 0.0485).CONCLUSIONS:Real-world data analysis suggests superior efficacy of nivolumab over molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma. |
| DOI | 10.1111/iju.14412 |
| PMID | 33159426 |